Mizuho raised the firm’s price target on Neurocrine (NBIX) to $146 from $145 and keeps a Neutral rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $147 from $124 at BMO Capital
- Neurocrine price target raised to $179 from $175 at Piper Sandler
- Neurocrine price target raised to $164 from $160 at Canaccord
- Neurocrine price target raised to $203 from $175 at Citi
- Neurocrine’s Strong Financial Performance and Growth Potential Justify Buy Rating